| Biomarker ID | 679 |
| PMID | 21723797 |
| Year | 2011 |
| Biomarker | miR-141 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Upregulated with increasing PSA |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 8.3 |
| Effect on Pathways | Pathways Include:- regulation of RNA metabolic process; Gene expression (Transcription); RNA Polymerase II Transcription; nuclear chromosome; DNA-binding transcription factor activity, RNA polymerase II-specific |
| Experiment | progression Vs No Progression |
| Type of Biomarker | Prognostic |
| Cohort | 21 patients with Prostate Cancer were chosen for this study |
| Senstivity | 78.9% |
| Specificity | 68.8% |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | miR-141 |